Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data In Support Of AV-101, A Novel Dry Powder Inhaled Formulation Of Imatinib, At The American Thoracic Society 2023 International Conference
Portfolio Pulse from Happy Mohamed
Aerovate Therapeutics presents nonclinical pharmacokinetic data supporting AV-101, a novel dry powder inhaled formulation of imatinib, at the American Thoracic Society 2023 International Conference. The data shows increased lung exposure compared to oral or IV dosing, suggesting potential for improved therapeutic profile in treating pulmonary arterial hypertension. Aerovate is currently recruiting for the IMPAHCT Phase 2b/Phase 3 trial.
May 22, 2023 | 5:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aerovate Therapeutics presents positive nonclinical data for AV-101, a novel inhaled imatinib formulation, at ATS 2023. The data suggests potential for improved treatment of pulmonary arterial hypertension.
The positive nonclinical data for AV-101 suggests that the inhaled formulation may provide improved treatment for pulmonary arterial hypertension. This could potentially lead to increased demand for the product and a positive impact on Aerovate Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100